Respiratory syncytial virus (RSV) is a significant cause of infant morbidity and mortality worldwide with peak hospitalization rates for RSV-mediated illnesses between 2 and 3 months of life. Until very recently, prevention strategies for RSV involved primarily passive immunization of neonates at high risk with monoclonal antibodies and promotion of breastfeeding. The Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices now recommends passive immunization of all neonates with monoclonal antibodies during RSV season, and the American Association of Pediatrics has endorsed this practice. The U.S. Food and Drug Administration (FDA) recently approved a vaccination for RSV in pregnancy. The CDC's Advisory Committee on Immunization Practices has recently recommended RSV vaccination for all pregnant patients between 32 and 36 weeks of gestation who are anticipated to deliver during RSV season if they are not planning nirsevimab for their infants. This recommendation has been endorsed by the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. In this clinical perspective, we review the scientific evidence, potential concerns, challenges, and future considerations for RSV vaccination in pregnancy.

中文翻译：

---

了解妊娠期呼吸道合胞病毒预防的新建议。

呼吸道合胞病毒 (RSV) 是全球婴儿发病和死亡的一个重要原因，RSV 介导的疾病住院率在出生后 2 至 3 个月内达到峰值。直到最近，RSV 的预防策略主要包括使用单克隆抗体对高危新生儿进行被动免疫和促进母乳喂养。美国疾病控制与预防中心 (CDC) 免疫实践咨询委员会现建议在 RSV 季节对所有新生儿进行单克隆抗体被动免疫，美国儿科协会也认可了这一做法。美国食品和药物管理局 (FDA) 最近批准了妊娠期 RSV 疫苗接种。 CDC 免疫实践咨询委员会最近建议所有妊娠 32 至 36 周的怀孕患者接种 RSV 疫苗，这些患者如果不计划为婴儿接种 nirsevimab，预计将在 RSV 季节分娩。该建议已得到美国妇产科医师学会和母胎医学学会的认可。从这个临床角度来看，我们回顾了妊娠期 RSV 疫苗接种的科学证据、潜在问题、挑战和未来考虑因素。